Brokerages Set ICON Public Limited (NASDAQ:ICLR) PT at $321.64

Shares of ICON Public Limited (NASDAQ:ICLR) have been assigned a consensus rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $339.44.

A number of equities research analysts have issued reports on ICLR shares. Mizuho reissued a “buy” rating and issued a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. Evercore ISI cut their price target on shares of ICON Public from $350.00 to $330.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. Robert W. Baird raised their price target on shares of ICON Public from $362.00 to $363.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. TD Cowen raised their price target on shares of ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Barclays raised their target price on shares of ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd.

ICON Public Price Performance

ICLR stock opened at $301.61 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21. ICON Public has a 52 week low of $181.92 and a 52 week high of $344.77. The firm’s fifty day moving average is $319.48 and its 200 day moving average is $284.10. The firm has a market cap of $24.88 billion, a P/E ratio of 36.45, a P/E/G ratio of 1.37 and a beta of 1.15.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. Research analysts predict that ICON Public will post 14.4 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ICLR. Bruce G. Allen Investments LLC purchased a new position in ICON Public during the 4th quarter valued at about $25,000. Livelsberger Financial Advisory purchased a new position in ICON Public in the fourth quarter worth about $29,000. Pinnacle Bancorp Inc. raised its holdings in ICON Public by 110.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after buying an additional 55 shares during the last quarter. Riverview Trust Co purchased a new position in ICON Public in the first quarter worth about $31,000. Finally, GAMMA Investing LLC purchased a new position in ICON Public in the fourth quarter worth about $37,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.